Skip to content

Auditory MMN EEG in TRD in Response to Ketamine

Treatment-resistant Depression (TRD)

To develop and test a neurocomputational model of ketamine treatment response predictions in TRD.

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    18 to 65

Participation Criteria

Inclusion Criteria:

1.18 to 65 years of age 2. Meeting Diagnostic and Statistical Manual for Mental Disorders (DSM-5) criteria for MDD and in a Major Depressive Episode and ≥10 on the Montgomery-Asberg Depression Rating Scale (MADRS).

3. Competent to consent-based on their ability to provide a spontaneous narrative description of the key elements of the study.

4. Failure of at least two trials of antidepressant therapy during the current episode (treatment-resistant depression) and receiving ketamine treatment clinically as administered by their clinician 5. Staying on stable dosages of any concomitant psychotropic medications.

Exclusion Criteria:

1. History of bipolar disorder or psychosis
2. Current substance use or history of substance use during the past year (excluding nicotine and caffeine use disorder)
3. Concomitant major and unstable medical or neurologic illness or a history of seizures.
4. Non-English-speaking individuals.

Study Location

St. Michael's Hospital
St. Michael's Hospital
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Venkat Bhat, MD MSc

4163604000
Study Sponsored By
Unity Health Toronto
Participants Required
More Information
Study ID: NCT05464264